Ironwood Historical Balance Sheet
IRWD Stock | USD 8.12 0.18 2.17% |
Trend analysis of Ironwood Pharmaceuticals balance sheet accounts such as Other Current Liabilities of 67.6 M or Total Current Liabilities of 289.9 M provides information on Ironwood Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Ironwood Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Ironwood Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Ironwood Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ironwood Pharmaceuticals is a good buy for the upcoming year.
Ironwood Pharmaceuticals Inventory |
|
Ironwood |
About Ironwood Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Ironwood Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Ironwood Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ironwood Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ironwood currently owns. An asset can also be divided into two categories, current and non-current.
Ironwood Pharmaceuticals Balance Sheet Chart
Ironwood Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Ironwood Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Ironwood Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 67.6 M, whereas Other Liabilities is forecasted to decline to about 8.3 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Ironwood Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ironwood Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Ironwood Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ironwood Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Ironwood Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 67.6 M, whereas Other Liabilities is forecasted to decline to about 8.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 475.8M | 415.9M | 715.5M | 751.3M | Total Assets | 1.1B | 1.1B | 471.1M | 499.5M |
Ironwood Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Short Long Term Debt Total | 431.2M | 453.7M | 475.8M | 415.9M | 715.5M | 751.3M | |
Other Current Liab | 33.4M | 540K | 1.3M | 22.0M | 64.3M | 67.6M | |
Total Current Liabilities | 40.9M | 32.7M | 161.7M | 25.5M | 276.1M | 289.9M | |
Total Stockholder Equity | (93.3M) | 62.6M | 605.9M | 652.4M | (346.3M) | (329.0M) | |
Other Liab | 25.0M | 13.3M | 3.5M | 9.8M | 8.8M | 8.3M | |
Property Plant And Equipment Net | 30.2M | 25.5M | 22.9M | 20.3M | 18.2M | 19.6M | |
Current Deferred Revenue | 875K | 28.4M | 39.5M | 1.2M | 1.1M | 1.1M | |
Net Debt | 254.2M | 91.1M | (144.3M) | (240.3M) | 623.4M | 654.6M | |
Retained Earnings | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (1.7B) | (1.6B) | |
Accounts Payable | 5.5M | 661K | 935K | 483K | 7.8M | 7.4M | |
Cash | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Non Current Assets Total | 95.9M | 63.4M | 381.7M | 319.9M | 237.8M | 143.0M | |
Non Currrent Assets Other | 64.9M | 37.1M | 25.5M | 15.9M | 3.6M | 3.4M | |
Other Assets | 64.9M | 54.5M | 358.8M | 299.6M | 1.0 | 0.95 | |
Long Term Debt | 408.0M | 430.3M | 337.3M | 396.3M | 498.3M | 252.1M | |
Cash And Short Term Investments | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Net Receivables | 117.2M | 122.4M | 114.0M | 115.5M | 129.1M | 135.6M | |
Common Stock Total Equity | 154K | 158K | 161K | 162K | 177.1K | 125.3K | |
Common Stock Shares Outstanding | 156.0M | 160.7M | 164.4M | 186.3M | 155.4M | 137.1M | |
Liabilities And Stockholders Equity | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Non Current Liabilities Total | 455.1M | 463.9M | 359.3M | 422.6M | 541.3M | 370.6M | |
Other Current Assets | 11.9M | 9.2M | 9.8M | 7.7M | 12.0M | 17.6M | |
Other Stockholder Equity | 1.5B | 1.5B | 1.5B | 1.3B | 1.4B | 1.0B | |
Total Liab | 496.0M | 496.6M | 521.0M | 448.1M | 817.4M | 454.8M | |
Property Plant And Equipment Gross | 30.2M | 25.5M | 22.9M | 20.3M | 27.1M | 20.1M | |
Total Current Assets | 306.9M | 495.8M | 745.2M | 780.6M | 233.3M | 356.5M | |
Accumulated Other Comprehensive Income | (79K) | (65.2M) | 0.0 | (11.8M) | (3.0M) | (3.2M) | |
Short Term Debt | 1.1M | 3.1M | 120.0M | 3.1M | 202.7M | 212.8M | |
Common Stock | 154K | 158K | 161K | 162K | 156K | 128.1K | |
Property Plant Equipment | 12.4M | 8.9M | 22.9M | 6.3M | 5.7M | 5.4M | |
Net Tangible Assets | (72.0M) | 83.0M | 605.9M | 669.0M | 769.3M | 807.8M | |
Retained Earnings Total Equity | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (626.7M) | (658.1M) | |
Long Term Debt Total | 408.0M | 430.3M | 337.3M | 396.3M | 455.7M | 311.5M | |
Capital Surpluse | 1.5B | 1.5B | 1.5B | 1.3B | 1.6B | 1.3B | |
Capital Lease Obligations | 23.2M | 23.4M | 21.6M | 19.7M | 17.7M | 9.9M | |
Deferred Long Term Liab | 97.6M | 40.1M | 24.3M | 12.1M | 13.9M | 13.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Transaction History View history of all your transactions and understand their impact on performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.